Announced Wed, 7 Oct, 2026 · 11:02 IST

Quarterly compliance certificate for dematerialization of shares

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹382.50

prior close

₹383.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+5.1% vs market

Specialty Chemicals peers, median of 99sector-0.2%+5.1% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.4

15m

-0.4

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9-0.2+5.1-0.2+5.1

Next day

+1.6-3.0+4.6-2.4+4.0

+4.2-2.7+6.9-2.6+6.7

+5.9-1.9+7.8-1.3+7.2

+3.8-1.7+5.5-1.2+5.0

+4.6-1.0+5.6-0.8+5.4

+6.4-2.0+8.4-1.3+7.7

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 99Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Titan Biotech has submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The certificate, issued by the company's Registrar and Share Transfer Agent (Beetal Financial and Computer Services), confirms that all securities received for demat during the quarter were processed, listed on the stock exchange, and the company's name was updated in the register of members within 15 days. This is a standard procedural filing required every quarter.

Likely market impact

Routine regulatory compliance. No material effect on shareholders or stock price.